Adaptive Biotechnologies Charts Profit Path After MRD Surge

Adaptive Biotechnologies ((ADPT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Adaptive Biotechnologies struck an upbeat tone on its earnings call, as management highlighted powerful momentum in its MRD testing franchise, expanding margins, and the first year of positive adjusted EBITDA. While GAAP net losses and Immune Medicine drag on profitability, executives argued the business now has multiple levers to sustain double‑digit growth and reach free‑cash‑flow breakeven in 2026.

Robust Top-Line Growth Across 2025

Total revenue for 2025 reached $277.0 million, up 55% year over year, with fourth‑quarter revenue climbing 51% to $71.7 million. Excluding noncash Genentech amortization, full‑year revenue was $235.7 million, representing a strong 42% annual growth rate driven largely by MRD testing demand.

MRD and clonoSEQ Remain the Growth Engine

MRD revenue grew 46% year over year to $212 million, including $19.5 million in milestones, underscoring clonoSEQ’s status as the company’s primary growth engine. Clinical testing revenue for clonoSEQ jumped 64% for the full year and 59% in Q4, with quarterly test volumes hitting a record 30,038, up 43% from a year ago and 11% sequentially.

ASP Expansion and Broad Payer Momentum

The company continued to push pricing higher, with U.S. average selling price rising 17% year over year to $1,307 per test and exiting the fourth quarter at roughly $1,350. Management credited renegotiated contracts with eight major payers and new agreements with large insurers for supporting a path toward a roughly $1,400 ASP by 2026.

Margin Gains From Scale and Sequencing Efficiencies

Sequencing gross margin, excluding milestones, licensing, and Genentech effects, reached 71% in Q4, a 12‑point improvement from the prior year. For 2025 the metric climbed to 66% from 53% in 2024, driven by production efficiencies and the transition to NovaSeq X+, which lowers unit costs as test volumes ramp.

Profitability Inflection and Solid Cash Cushion

Adjusted EBITDA swung to a positive $12.2 million for 2025 from a loss of $80.4 million a year earlier, with Q4 adjusted EBITDA of $4.1 million versus a $16.4 million loss. The MRD segment produced $15.2 million of positive adjusted EBITDA, and the company ended the year with $227 million in cash, cash equivalents, and marketable securities.

Commercial Execution and Channel Expansion

Operationally, growth was broad‑based, with blood‑based tests rising to 47% of clonoSEQ volume in Q4, up from 41% a year earlier, making access easier for community doctors. Community settings accounted for about one‑third of tests, Epic integrations expanded to 173 accounts that now drive roughly 40% of orders, and commercial payer cash collections climbed 74% year over year.

Immune Medicine Scale and Pfizer Partnerships

Immune Medicine has now cataloged more than five million paired TCRs across about 20,000 antigens and 50 HLA types, creating a sizable data asset. Revenue from this segment rose to $9.8 million in Q4 from $3.8 million and to $23.4 million for the year, up 17%, bolstered by two Pfizer agreements focused on data licensing and target discovery.

Clear 2026 Growth Algorithm and Cash-Flow Path

Management laid out 2026 MRD revenue guidance of $255 million to $265 million, implying about 22% growth, or around 30% excluding milestones, with modest weighting toward the second half. clonoSEQ volumes are expected to increase more than 30%, blood‑based testing should surpass half of MRD volume, community share should exceed 35%, and the company aims for positive adjusted EBITDA and free cash flow exiting 2026.

GAAP Losses Persist Despite EBITDA Turnaround

Despite the move into positive adjusted EBITDA, Adaptive reported a 2025 net loss of $59.5 million and a Q4 loss of $13.6 million, reflecting ongoing noncash and operating costs. Investors are being asked to look through these GAAP numbers to the improving underlying economics of the MRD segment and the accelerating contribution from higher‑margin sequencing revenue.

Immune Medicine Still a Drag on Earnings

The Immune Medicine unit remained loss‑making, posting an adjusted EBITDA loss of $31.0 million in 2025, though this improved from a $37.9 million loss in 2024. Management expects the segment’s net cash burn to narrow materially, targeting $15 million to $20 million in 2026 as data monetization expands and spending becomes more selective.

Payer Timing and ASP Targets Add Execution Risk

The 2026 ASP goal of about $1,400 per test depends partly on closing two large national payer contracts, introducing some uncertainty around timing and pricing. Management warned that negotiations could cause ASP volatility through the year, even as they remain confident in the long‑term upward trajectory supported by broader coverage and better collections.

Impact of Genentech Wind-Down on Revenue Mix

The acceleration of Genentech collaboration amortization in Q3 and the end of that relationship remove a meaningful noncash revenue tailwind. With no further economics from the collaboration after Q3, investors will see a cleaner revenue base, but the company must now rely even more on core commercial growth and pharma data deals to sustain its top line.

Competitive and Operational Headwinds to Monitor

Management acknowledged new offerings like Quest’s flow cytometry test that could introduce pricing or share pressures, despite claims of lower sensitivity than clonoSEQ. Operational risks also surfaced, with seasonality and disruptions such as FedEx outages and clinic closures impacting Q1 volumes, underscoring the potential for short‑term volatility in test counts.

Elevated Operating Expenses Reflect Continued Investment

Operating expenses totaled $334.1 million in 2025, down 2% from the prior year, but guidance calls for $350 million to $360 million in 2026, roughly 6% growth at the midpoint. The higher cost base signals continued investment in commercial infrastructure, R&D, and data capabilities even as management pushes toward cash‑flow breakeven.

Guidance Underscores Confidence in Growth and Cash Turning Positive

For 2026, the company expects MRD revenue of $255 million to $265 million with about 45% of sales in the first half and 55% in the second, alongside clonoSEQ volume growth above 30% and ASPs around $1,400. Operating expenses are projected at $350 million to $360 million, Immune Medicine cash burn should narrow, and management expects the business to exit 2026 with both adjusted EBITDA and free cash flow firmly in positive territory.

Adaptive Biotechnologies’ call painted a picture of a company transitioning from a high‑growth, cash‑burning model to a more disciplined, margin‑expanding operator anchored by its MRD franchise. While GAAP losses, Immune Medicine investment, and competitive and payer risks persist, the outlined path to positive free cash flow in 2026 and ongoing pricing and volume gains in clonoSEQ will likely be central to how investors value the stock over the next two years.